Skip to main content
AstraZenecaEarnings

AstraZeneca stock opens new Massachusetts research center

Source: Autobound Signal API · 80 signals tracked for AstraZeneca · updated

Get AstraZeneca's live signals in Claude or ChatGPT, or by API

AskWhat changed at AstraZeneca this week? Use Autobound signals for astrazeneca.com.

What happened

AstraZeneca reported quarterly EPS of USD 2.63 for Q2 2026.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

AstraZeneca stock (ISIN GB0009895292) was trading at GBp 11,889.92 on the London Stock Exchange on October 5, 2026, with a 0.17 percent gain for the session. The company opened a new global strategic research and development center in Kendall Square, Cambridge, Massachusetts, according to Business Wire on October 5, 2026. The Kendall Square facility extends AstraZeneca's existing presence in Cambridge and Boston and places its scientists inside a major US life sciences cluster. The opening gives the company a fresh operational focus as it continues building medicines across oncology, rare disease and biopharmaceuticals. The event follows AstraZeneca's completed USD 2 billion equity investment in Summit Therapeutics, which supports development of the cancer drug ivonescimab in combination with antibody drug conjugates. That transaction and the new research center both connect the companys capital spending with its oncology pipeline. AstraZeneca reported Q2 2026 revenue of USD 15.38 billion, up 6.4 percent from the prior-year quarter, while quarterly EPS reached USD 2.63 versus a USD 2.50 consensus estimate, according to MarketBeat . The figures show the tension in the current setup: revenue growth remains positive, while the share price is still well below its annual peak. The LSE quote's October 5 range was GBp 11,864.00 to GBp 11,944.00, with volume of 229,600 shares. Its...

Keep reading with a free account

The rest of this article, and every signal for AstraZeneca, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Earnings

What this signalsEarnings results often set the next budget cycle.

The full record

From the Signal API record

Extraction

Confidence
90%
Detected
Oct 5, 2026
signal_type
news
signal_subtype
has_earnings

Use this data

Get every earnings signal for AstraZeneca and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AstraZeneca this week?”

  2. Send it to your own tools

    The Signal API returns earnings signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/08811e56-9c43-7a01-622c-edef9eda0d07 returns this record as JSON. POST /v1/companies/enrich returns every signal for astrazeneca.com.

{
  "signal_id": "08811e56-9c43-7a01-622c-edef9eda0d07",
  "signal_type": "news",
  "signal_subtype": "has_earnings",
  "detected_at": "2026-10-05T20:53:09+00:00",
  "company": {
    "name": "AstraZeneca",
    "domain": "astrazeneca.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/astrazeneca-stock-opens-new-massachusetts-research-center/70237350",
    "title": "AstraZeneca stock opens new Massachusetts research center - AD HOC NEWS",
    "excerpt": "AstraZeneca stock (ISIN GB0009895292) was trading at GBp 11,889.92 on the London Stock Exchange on October 5, 2026, with a 0.17 percent gain for the session. The company opened a new global strategic research and development center in Kendall Square, Cambridge, Massachusetts, according to Business Wire on October 5, 2026. The Kendall Square facility extends AstraZeneca's existing presence in Cambridge and Boston and places its scientists inside a major US life sciences cluster. The opening gives the company a fresh operational focus as it continues building medicines across oncology, rare disease and biopharmaceuticals. The event follows AstraZeneca's completed USD 2 billion equity investment in Summit Therapeutics, which supports development of the cancer drug ivonescimab in combination with antibody drug conjugates. That transaction and the new research center both connect the companys capital spending with its oncology pipeline. AstraZeneca reported Q2 2026 revenue of USD 15.38 billion, up 6.4 percent from the prior-year quarter, while quarterly EPS reached USD 2.63 versus a USD 2.50 consensus estimate, according to MarketBeat . The figures show the tension in the current setup: revenue growth remains positive, while the share price is still well below its annual peak. The LSE quote's October 5 range was GBp 11,864.00 to GBp 11,944.00, with volume of 229,600 shares. Its...",
    "summary": "AstraZeneca reported quarterly EPS of USD 2.63 for Q2 2026.",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2705372_1920_1080.webp",
    "confidence": 0.9,
    "published_at": "2026-10-05T20:53:09Z",
    "article_sentence": "AstraZeneca reported Q2 2026 revenue of USD 15.38 billion, up 6.4 percent from the prior-year quarter, while quarterly EPS reached USD 2.63 versus a USD 2.50 consensus estimate, according to MarketBeat ."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.